Summary

for people ages up to 24 months (full criteria)
at San Francisco, California and other locations
study started
estimated completion:
Hannah C Glass

Description

Summary

The purpose of this study is to examine whether the duration of treatment with phenobarbital has an impact on neurodevelopmental and epilepsy outcomes, as well as parent and family well-being, after neonatal seizures.

Details

The Nature of the comparison analysis for parent and family well-being is yet to be determined with our Parent Partner Advisory Board.

Keywords

Neonatal Seizures Phenobarbital EEG family impact neurodevelopment Seizures Anticonvulsants Surveys NICU Enrollees

Eligibility

You can join if…

Open to people ages up to 24 months

  • Neonates <44 weeks corrected age at seizure onset
  • Seizures due to acute brain injury
  • Parent(s) who are English or Spanish literate (with assistance of interpreter)

You CAN'T join if...

  • Neonates at risk for adverse outcome independent of seizures and underlying brain injury
  • Neonates with mild, temporary causes for seizures
  • Newborns with neonatal-onset epilepsy syndromes
  • Neonates who do not survive the initial hospital admission
  • Neonates will not be excluded based on race, ethnicity, gender or gestational age

Locations

  • University of California, San Francisco
    San Francisco California 94143 United States
  • Stanford University
    Stanford California 94304 United States

Lead Scientist

  • Hannah C Glass
    Dr. Hannah Glass is a pediatric neurologist, founding co-director of the Neurointensive Care Nursery (NICN), and Director of Neonatal Critical Care Services at the UCSF Benioff Children's Hospital. She is also the program director of the Neonatal Neurology Fellowship Program.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of Michigan
Links
PCORI website
ID
NCT02789176
Study Type
Observational
Last Updated